Search
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalPlecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years o...
NKX101
go.drugbank.com/drugs/DB18131InvestigationalNKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15NS-3728
go.drugbank.com/drugs/DB05835ExperimentalNS3728 is an orally active chloride channel blocker for the treatment of cancer.
Vapitadine
go.drugbank.com/drugs/DB05738ExperimentalAn advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis
Sonesitatug Vedotin
go.drugbank.com/drugs/DB18619InvestigationalCMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.
Synonyms: an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payloadZotarolimus
go.drugbank.com/drugs/DB18761InvestigationalZotarolimus is an immunosuppressant under investigation for use in drug-eluting stents.
APT3111
go.drugbank.com/drugs/DB06390ExperimentalAPT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on Ma...
Satavaptan
go.drugbank.com/drugs/DB14923InvestigationalSatavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).